Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-06-04
|
aglatimagene besadenovec (AdV-tk) followed by valacyclovir |
malignant pleural effusion |
1b |
Advantagene (USA - MA) |
Cancer - Oncology |
2016-06-03
|
BAY-1841788/ODM-201 in combination with standard androgen deprivation therapy and docetaxel |
metastatic hormone sensitive prostate cancer |
3 |
Orion Corporation (Finland) Bayer (Germany) |
Cancer - Oncology |
2016-06-03
|
Actimab-A - Lintuzumab-Ac225 |
newly diagnosed acute myeloid leukemia (AML) in elderly patients |
1-2 |
Actinium Pharmaceuticals (USA - NJ) |
Cancer - Oncology |
2016-06-03
|
abemaciclib (LY2835219) |
metastatic breast cancer |
2 |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2016-06-02
|
TG02 and pembrolizumab |
locally recurrent RAS mutated rectal cancer |
1 |
Targovax (Norway) |
Cancer - Oncology |
2016-06-02
|
ofatumumab |
relapsing multiple sclerosis |
3 |
Novartis (Switzerland) |
Neurodegenerative diseases |
2016-06-02
|
ofatumumab |
relapsing multiple sclerosis |
3 |
Novartis (Switzerland) |
Neurodegenerative diseases |
2016-06-02
|
Beleodaq® oral formulation (belinostat) |
|
preclinical |
Onxeo (France) |
Cancer - Oncology - Rare diseases |
2016-06-02
|
Xtandi® (enzalutamide) and paclitaxell |
triple-negative breast cancer (TNBC) |
3 |
Medivation (USA - CA) Astellas (Japan) |
Cancer - Oncology |
2016-06-02
|
Pseudomonas aeruginosa vaccine IC43/VLA43 |
Pseudomonas aeruginosa infection |
2-3 |
Intercell now Valneva (France - Austria) Novartis (Switzerland) |
Infectious diseases |
2016-06-01
|
anamorelin |
non-small cell lung cancer (NSCLC) |
3 |
Helsinn Group (Switzerland) |
Cancer - Oncology |
2016-06-01
|
Catena®/Raxone® (idebenone) |
Duchenne Muscular Dystrophy (DMD) |
3 |
Santhera Pharmaceuticals (Switzerland) |
Genetic diseases - Neuromuscular diseases - Rare diseases |
2016-06-00
|
cobimetinib and atezolizumab |
colorectal cancer |
3 |
Roche (Switzerland) |
Cancer - Oncology |
2016-05-31
|
MBX-8025 (2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate) |
primary biliary cholangitis |
2 |
Cymabay Therapeutics (USA - CA) |
Rare diseases - Hepatic diseases - Liver diseases |
2016-05-31
|
AP32788 |
non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2 |
1 |
Ariad Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-05-31
|
evinacumab (REGN1500) |
homozygous familial hypercholesterolemia |
2 |
Regeneron Pharmaceuticals (USA - NY) |
Rare diseases - Genetic diseases - Metabolic diseases |
2016-05-31
|
prurisol |
moderate chronic plaque psoriasis |
2a |
Innovation Pharmaceuticals (USA - MA) |
Autoimmune diseases - Dermatological diseases |
2016-05-27
|
betrixaban |
prevention of venous thromboembolism (VTE) |
3 |
Portola Pharmaceuticals |
Cardiovascular diseases |
2016-05-27
|
Gazyva®/Gazyvaro® (obinutuzumab) |
non-Hodgkin's lymphoma |
3 |
Roche (Switzerland) |
Cancer - Oncology |
2016-05-26
|
OvaSave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) |
|
preclinical |
Txcell (France) |
|